NovaBay Pharmaceuticals, Inc.

NBY · AMEX
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income-$7,210-$6,145-$10,608-$5,824
Dep. & Amort.$381$356$483$119
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$0$220$1,153
Change in WC-$595-$433$533-$38
Other Non-Cash$2,241$1,961$2,718-$4,602
Operating Cash Flow-$5,183-$4,261-$6,654-$9,192
Investing Activities
PP&E Inv.-$6-$19-$112-$52
Net Acquisitions$1,070$0$0-$11,993
Inv. Purchases$0$0$0$0
Inv. Sales/Matur.$0$0$0$0
Other Inv. Act.$0$0$0$0
Investing Cash Flow$1,064-$19-$112-$12,045
Financing Activities
Debt Repay.-$1,490$1,526-$105$105
Stock Issued$3,105$565$0$1,776
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$115-$181$4,738$14,908
Financing Cash Flow$1,500$1,910$4,633$16,789
Forex Effect$125-$68$0$0
Net Chg. in Cash-$2,494-$2,438-$2,133-$4,448
Supplemental Information
Beg. Cash$2,924$5,362$7,979$12,427
End Cash$430$2,924$5,846$7,979
Free Cash Flow-$5,189-$4,280-$6,766-$9,244
NovaBay Pharmaceuticals, Inc. (NBY) Financial Statements & Key Stats | AlphaPilot